The neuroprotective properties of FAAH inhibitors and the therapeutic efficacy of anti-cholinesterase agents were combined obtaining hybrid FAAH/COXs inhibitors, potentially useful for the treatment of AD [179]. This evidence concerns the gene FAAH and Alzheimer disease.